Twitter And 20 Stocks Moving Premarket

Gainers Seritage Growth Properties (NYSE: SRG) rose 35.7% to $8.25 in pre-market trading after gaining around 10% on Thursday. Seritage Growth Properties filed its preliminary proxy materials with the U.S. Securities and Exchange Commission.

Gainers

  • Seritage Growth Properties (NYSE:SRG) rose 35.7% to $8.25 in pre-market trading after gaining around 10% on Thursday. Seritage Growth Properties filed its preliminary proxy materials with the U.S. Securities and Exchange Commission.
  • Insignia Systems, Inc. (NASDAQ:ISIG) rose 33.1% to $10.78 in pre-market trading after gaining around 6% on Thursday.
  • Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) rose 27.4% to $0.2689 in pre-market trading after gaining around 19% on Thursday. Allena Pharmaceuticals recently announced rescheduling of special meeting to approve reverse stock split.
  • Aprea Therapeutics, Inc. (NASDAQ:APRE) rose 18.9% to $0.9511 in pre-market trading. Wedbush initiated coverage on Aprea Therapeutics with an Outperform rating and announced a price target of $3.
  • Clovis Oncology, Inc. (NASDAQ:CLVS) rose 12.4% to $2.44 in pre-market trading. Clovis Oncology said on July 1, it had a Type A meeting with the FDA.
  • Aqua Metals, Inc. (NASDAQ:AQMS) rose 11.3% to $0.8575 in pre-market trading.
  • Aeterna Zentaris Inc. (NASDAQ:AEZS) rose 9.3% to $0.2278 in pre-market trading. Aeterna Zentaris announced further adjournment of shareholder meeting.
  • MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) rose 8.6% to $3.25 in pre-market trading after gaining 9% on Thursday.
  • MediaCo Holding Inc. (NASDAQ:MDIA) rose 8.1% to $3.07 in pre-market trading after gaining 5% on Thursday.
  • Evofem Biosciences, Inc. (NASDAQ:EVFM) rose 6.4% to $1.33 in pre-market trading after declining 6% on Thursday.

Don’t forget to check out our premarket coverage here .

Losers

  • Enjoy Technology, Inc. (NASDAQ:ENJY) fell 37.7% to $0.25 in pre-market trading. Enjoy Technology said that the company received a written notice from NASDAQ on delisting.
  • Upstart Holdings, Inc. (NASDAQ:UPST) fell 17.9% to $27.69 in pre-market trading after the company reported preliminary results for the second quarter. The company said it sees Q2 preliminary revenue of $228 million, versus earlier forecast of $295 million to $305 million. Net loss is seen in the range of $31 million to $27 million.
  • American Rebel Holdings, Inc. (NASDAQ:AREB) shares fell 9.2% to $1.08 in pre-market trading. American Rebel shares jumped 56% on Thursday after the company announced it has entered an agreement to acquire Champion Safe Company in a transaction valued at approximately $9.9 million.
  • SCWorx Corp. (NASDAQ:WORX) shares fell 8.6% to $0.72 in pre-market trading. SCWorx recently announced a common stock purchase agreement with an institutional investor for up to $5 million.
  • Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) fell 8% to $0.69 in pre-market trading.
  • Grove Collaborative Holdings, Inc. (NASDAQ:GROV) fell 7.9% to $6.79 in pre-market trading. Grove Collaborative shares jumped 84% on Thursday after the company announced retail expansion into Kohl’s, Giant Eagle and Meijer.
  • AcelRx Pharmaceuticals, Inc (NASDAQ:ACRX) fell 6.5% to $0.33 in pre-market trading after jumping 36% on Thursday.
  • Atlassian Corporation Plc (NASDAQ:TEAM) fell 6.4% to $200.00 in pre-market trading.
  • GameStop Corp. (NYSE:GME) shares fell 6% to $126.97 in pre-market trading. GameStop fired its CFO, Mike Recupero and is also reportedly planning company-wide layoffs. The company also announced appointment of Diana Saadeh-Jajeh as CFO, effective immediately.
  • Twitter, Inc. (NYSE:TWTR) fell 4.2% to $37.16 in pre-market trading. Wedbush maintained Twitter with a Neutral and lowered the price target from $54 to $43.
  • Prudential plc (NYSE:PUK) fell 3.7% to $24.00 in pre-market trading after gaining more than 4% on Thursday.
Total
0
Shares
Related Posts
Read More

Sana Biotechnology Announces Publication Of Preclinical Diabetes Data In Cell Stem Cell Demonstrating Insulin Independence Following Transplantation Of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression In A Diabetic NHP

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression

SANA